AstraZeneca secures orders for 400 million doses of COVID-19 vaccine

Published On 2020-05-24 05:45 GMT | Update On 2020-05-24 05:45 GMT

London: Drugmaker AstraZeneca secured its first agreements Thursday for 400 million doses of a COVID-19 vaccine, bolstered by an investment from the U.S. vaccine agency.

The Anglo-Swedish company reported it had received more than $1 billion from the U.S. Biomedical Advanced Research and Development Authority for the development, production, and delivery of the vaccine, starting this fall.

The investment will accelerate the development and production of the vaccine, AstraZeneca Chief Executive Pascal Soriot said. It had already joined forces with the British government.

"We will do everything in our power to make this vaccine quickly and widely available," he said.

Pharmaceutical companies including also Moderna and Sanofi are racing to develop and produce a vaccine against the new coronavirus as experts say it will be crucial to allowing countries to ease their lockdowns and restrictions on public life.

In a statement as markets opened, AstraZeneca said it has now secured manufacturing capacity for 1 billion doses and aims to secure further agreements to expand capacity further over the next months "to ensure the delivery of a globally accessible vaccine.''

The company also finalized its license agreement with Oxford University for the vaccine, now known as AZD1222.

The vaccine was developed by Oxford University's Jenner Institute, working with the Oxford Vaccine Group.

Article Source : AP

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Ruchika Sharma

Ruchika Sharma joined Medical Dialogue as an Correspondent for the Business Section in 2019. She covers all the updates in the Pharmaceutical field, Policy, Insurance, Business Healthcare, Medical News, Health News, Pharma News, Healthcare and Investment. She has completed her B.Com from Delhi University and then pursued postgraduation in M.Com. She can be contacted at editorial@medicaldialogues.in Contact no. 011-43720751

Comments Policy

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

AstraZeneca secures orders for 400 million doses of COVID-19 vaccine

Similar News

8 Drug Batches from 3 Pharma Firms Banned in Punjab After ADR Reports

Torrent-JB Chemicals Rs 25,689 Crore Merger Under CCI Lens Over Monopoly Concerns

Alkem Labs Gets CDSCO Panel Nod for conducting Phase III study of Semaglutide tablet

Reliance Life Sciences Gets CDSCO Panel Nod for Phase I/III Trial of Biosimilar Nivolumab

WHO issues alert over contaminated India cough syrups

Mankind Pharma MD Rajeev Juneja takes over as PHDCCI President

Raid: Raebareli Pharma agency sealed over purchase of 1.4 lakh bottles of codeine syrup

Abbvie gets USFDA approval for updated indication statement for Rinvoq for Inflammatory Bowel Disease